Becton, Dickinson and Company (NYSE:BDX) Releases Earnings Results, Beats Estimates By $0.43 EPS

Becton, Dickinson and Company (NYSE:BDX) posted its quarterly earnings results on Wednesday. The medical instruments supplier reported $3.43 EPS for the quarter, topping analysts’ consensus estimates of $3.00 by $0.43, Zacks reports. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. Becton, Dickinson and Company updated its FY 2025 guidance to 14.300-14.600 EPS.

Becton, Dickinson and Company Stock Up 1.1 %

Shares of NYSE:BDX opened at $245.07 on Thursday. The firm has a fifty day moving average price of $231.79 and a two-hundred day moving average price of $234.09. The company has a market cap of $71.07 billion, a price-to-earnings ratio of 41.26, a PEG ratio of 1.80 and a beta of 0.40. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $251.99.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be given a $1.04 dividend. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.70%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 70.03%.

Becton, Dickinson and Company announced that its board has initiated a stock buyback program on Tuesday, January 28th that permits the company to repurchase 10,000,000 outstanding shares. This repurchase authorization permits the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 597 shares of the firm’s stock in a transaction dated Friday, January 17th. The stock was sold at an average price of $236.51, for a total transaction of $141,196.47. Following the transaction, the executive vice president now directly owns 5,544 shares of the company’s stock, valued at approximately $1,311,211.44. This trade represents a 9.72 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP David Shan sold 500 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total value of $120,000.00. Following the sale, the executive vice president now owns 5,741 shares of the company’s stock, valued at $1,377,840. This represents a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 9,844 shares of company stock valued at $2,210,716. 0.36% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

BDX has been the topic of a number of recent research reports. StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Piper Sandler increased their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 28th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $283.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.